Resources

Shigella is the leading bacterial cause of childhood diarrhea, and infections can have long-term effects on growth and development. No licensed Shigella vaccines currently exist, but several promising candidates in development could become available in a few years.PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. This included: vaccine impact and cost-effectiveness analyses, demand forecasts for two potential markets, an expert consultation on Shigella-containing combination vaccines, and a feasibility and acceptability study with national stakeholders and healthcare providers in five countries. This brief provides a comprehensive summary of the results.

PATH helps policymakers and advocates make evidence-based policy and funding decisions to advance health equity. Leveraging PATH's nearly 50 years of experience developing and delivering health innovations and services for women and children, our advocates collect, analyze, package, and use data to inform policies, mobilize resources, engage citizens, and hold decision-makers accountable. This fact sheet details how PATH is driving change at the intersection of advocacy and technical assistance to help women and children around the world survive and thrive.

Technology updates provide the current product development status of the innovations our medical device and health technology teams are advancing. Each of these one-page documents provide high-level information covering health need, project partners, countries, funders, manufacturers, and the most current product development activities.Technology updates focus on innovations in the areas of vaccine and pharmaceutical formulation, product packaging and delivery, and supply systems and equipment, as well as innovations aimed at improving infant, child, and reproductive health. A few of the technology examples include, The Ellavi Uterine Balloon Tamponade (UBT), the Caya Diaphragm, autodisable (AD) syringes, microarray patches (MAPs), solar energy harvest control (EHC), freeze-preventive vaccine carrier, heat stable oral tablets for diabetes management, and mRNA formulation innovations.

User research in low-resource primary health care settings to inform decisions, and better understand and define user and health system constraints related to integrating smartphones and multimodal devices into integrated management of childhood illness (IMCI) practices.

This fact sheet provides an overview of the novel oral polio vaccine (nOPV) program—a consortium of PATH and partners that are working to advance novel vaccine candidates that will enable complete eradication and minimize the risk of polio resurgence.